Fenbendazole as a potential anticancer drug (2013)

Peer-Reviewed Study · Duan Q; Liu Y; Rockwell S · February 2013

Duan Q et al., 2013-02: Yale's follow-up of the Johns Hopkins observation: in EMT6 mouse mammary tumour cells and solid tumours, fenbendazole was cytotoxic in culture but did not slow tumour growth in mice or improve radiotherapy. The authors' own conclusion is that the studies provided no evidence fenbendazole would have value in cancer therapy.

These studies provided no evidence that fenbendazole would have value in cancer therapy, but suggested that this general class of compounds merits further investigation.

p.355 (abstract)

Duan Q et al., 2013-02: Yale's follow-up of the Johns Hopkins observation: in EMT6 mouse mammary tumour cells and solid tumours, fenbendazole was cytotoxic in culture but did not slow tumour growth in mice or improve radiotherapy. The authors' own conclusion is that the studies provided no evidence fenbendazole would have value in cancer therapy. Study type: cell-line and animal study. Cells: EMT6 mouse mammary tumour; mice bearing EMT6 solid tumours (number of animals not stated in the abstract). Country: United States (Yale University). Dose/route/schedule: 'maximally-intensive regimens' of fenbendazole, dose and schedule given in the full methods (not in the quoted abstract). Comparator: radiation alone, docetaxel alone, untreated controls. Funder: NCI grants P01 CA129186 and CA129186-03S2; Yale Cancer Center core facilities (NCI center grant 16359). Conflicts: none stated. Drug maker: not named. The paper states fenbendazole's mechanisms overlap with hypoxia-selective cytotoxins and taxanes – the basis later used by advocates – yet its in vivo result was null. Recorded as the strongest contrary finding in this run. Excerpt is the paper's own concluding sentence, quoted continuously (an earlier draft spliced it to the preceding sentence and was corrected). Study type: animal.